Question

Difficulty: HardPharmacologic Interventions

A 48-year-old man is evaluated in the hospital for a 3-day history of fever, pleuritic chest pain, and hemoptysis. He underwent a deceased-donor renal transplant 4 months ago for end-stage renal disease secondary to IgA nephropathy. His current medications include tacrolimus, mycophenolate mofetil, and prednisone. Temperature is 38.4∘C38.4^\circ\text{C} (101.1∘F101.1^\circ\text{F}), blood pressure is 130/80 mmHg130/80\text{ mmHg}, pulse is 98/min98/\text{min}, and respiratory rate is 18/min18/\text{min}. Laboratory studies show a serum creatinine of 1.4 mg/dL1.4\text{ mg/dL}. A CT scan of the chest demonstrates a right upper lobe cavitary lesion with a surrounding halo of ground-glass opacity. Serum galactomannan assay is prominently elevated. The attending physician plans to initiate the first-line targeted antimicrobial therapy for this patient's opportunistic infection. Which of the following is the most appropriate concurrent pharmacologic management step?

  1. Decrease the current dose of tacrolimusAnswer
  2. B
    Replace tacrolimus with cyclosporine
  3. C
    Initiate intravenous fluconazole instead of the planned therapy
  4. D
    Initiate liposomal amphotericin B instead of the planned therapy
  5. E
    Maintain the current tacrolimus dose and recheck serum creatinine in 14 days

Answer

Decrease the current dose of tacrolimus
The patient's clinical presentation, chest imaging showing a halo sign, and a positive serum galactomannan assay confirm the diagnosis of invasive pulmonary aspergillosis. The gold-standard treatment for this opportunistic infection is voriconazole. A critical pharmacologic principle in transplant medicine is managing the predictable drug-drug interaction between triazole antifungals and calcineurin inhibitors. Voriconazole strongly inhibits the cytochrome P450 3A4 (CYP3A4) enzyme. Tacrolimus is a narrow-therapeutic-index medication that relies heavily on CYP3A4 for its metabolism. Initiating voriconazole without adjusting the tacrolimus dose will rapidly cause toxic serum concentrations of tacrolimus, leading to acute kidney injury and neurotoxicity. Therefore, the most appropriate concurrent pharmacologic intervention is to preemptively decrease the tacrolimus dose (often by 30% to 50%) and to rigorously monitor tacrolimus trough levels over the subsequent days.

Step-by-Step Solution

1
Diagnose the opportunistic infection based on clinical and radiographic findings.
The triad of fever, pleuritic chest pain, and hemoptysis in a transplant patient, combined with a cavitary lesion showing a halo sign and a positive galactomannan assay, indicates invasive pulmonary aspergillosis.
Accurate diagnosis is required to anticipate the correct antimicrobial therapy.
2
Identify the standard first-line pharmacotherapy for the diagnosed infection.
Intravenous voriconazole is the primary targeted therapy for invasive aspergillosis.
The planned therapy acts as the trigger for potential drug interactions.
3
Analyze the pharmacokinetic properties of the intended antimicrobial.
Voriconazole is widely known as a potent inhibitor of the hepatic cytochrome P450 3A4 (CYP3A4) enzyme system.
Recognizing enzyme inhibition is critical when managing polypharmacy in complex patients.
4
Assess the patient's current medication list for significant interactions.
Tacrolimus is a narrow-therapeutic-index calcineurin inhibitor that is almost exclusively metabolized by CYP3A4.
Identifying the vulnerable substrate prevents iatrogenic toxicity.
5
Determine the necessary concurrent pharmacologic intervention.
The tacrolimus dose must be empirically decreased (usually by one-third to one-half) concurrently with the initiation of voriconazole, followed by close monitoring of trough levels.
Preemptive dose reduction prevents dangerous accumulations of tacrolimus that lead to acute nephrotoxicity.

Key Concept

Management of potent CYP3A4-mediated drug interactions, specifically preemptive dose reduction of calcineurin inhibitors (like tacrolimus) when initiating triazole antifungals.
Rate this question